News

Weight-loss drug Wegovy can be marketed for heart benefits after FDA label update

todayMarch 8, 2024 7

Background
share close
The US Food and Drug Administration approved drugmaker Novo Nordisk’s application to add cardiovascular benefits to the medicine’s label, making it the first weight-loss drug to also be cleared to reduce the risk of heart attack, stroke or heart-related death in people at higher risk of these conditions.

​ The US Food and Drug Administration approved drugmaker Novo Nordisk’s application to add cardiovascular benefits to the medicine’s label, making it the first weight-loss drug to also be cleared to reduce the risk of heart attack, stroke or heart-related death in people at higher risk of these conditions. Read More Breaking News, Latest News and Videos | CNN 

Written by:

Rate it